



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
PATENT 2 4 2003
PC11830ARTR
TECH CENTER 1600/2900

IN RE APPLICATION OF:

Mylari

: EXAMINER: Kevin E. Weddington

SERIAL NO.: 09/997,039

: ART UNIT: 1614

FILED: November 29, 2001

:

FOR: Combination of GABA Agonists and
Aldose Reductase Inhibitors

:

Asst. Commissioner for Patents
Washington, DC 20231

LETTER AND SUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Dear Assistant Commissioner:

In the matter of the above-identified application it is noted that the Applicants submitted an Information Disclosure Statement (IDS) on February 12, 2003, and it was received in (i.e., date stamped into) the Patent Office on February 19, 2003. A copy of the IDS, including Form PTO-FB-A820, is attached hereto as Exhibit A.

Applicants have not received a return copy of Form PTO-FB-A820, with the Examiner's initials next to each reference contained therein.

Accordingly, the Examiner is requested to review the references previously submitted and place his initials next to each on Form PTO-FB-A820 so as to indicate his review. Copies of these originally submitted references are again enclosed for the Examiner's review.

A copy of the return postcard for this application, showing receipt by the Office of the IDS and references, is included herewith. If anything further is needed, the Examiner is urged to telephone the undersigned at 860-715-5590.

No fee is thought to be due for this submission because no fee was due when the submission (IDS) was originally made. If the Commissioner determines that any fee is due however, please charge it to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Date: Apr 17/2003

Respectfully submitted,


William F. Mulholland, II
Attorney for Applicant
Reg. No. 45,684

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 715-5590

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

this 17th day of April 2003

By



Attorney Check No. PC11830ARTR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 12th day of February 2003.

By

(Signature of person mailing)

Patricia Botelho

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Banavara L. Mylari

Examiner: K.E. Weddington

APPLICATION NO.: 09/997,039

FILING DATE: November 29, 2001

: Group Art Unit: 1614

TITLE: Combination of GABA Agonists and Aldose
Reductase Inhibitors

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

February 12, 2003

Robert T. Ronau
Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, Box MS 8260-611
Eastern Point Road
Groton, CT 06340
(860) 441-5910


RECEIVED
APR 24 2003
TECH CENTER 1600/2300



EXHIBIT A

Date Mailed: February 12, 2003 Express Mail No. _____
Application No. 09/997,039 Docket No. PC11830ARTR By PB
Application of Banavara L. Mylari
Entitled Combination of GABA Agonists and Aldose Reductase Inhibitors
The following, due _____ in the U.S. Patent and Trademark Office, has been received there on the date stamped hereon:

<input type="checkbox"/> Specification _____ pages	<input type="checkbox"/> Amendment
<input type="checkbox"/> Claims _____ pages	<input type="checkbox"/> Reply
<input type="checkbox"/> Abstract _____ pages	<input type="checkbox"/> Notice of Appeal
<input type="checkbox"/> Drawing(s) _____ sheets	<input type="checkbox"/> Brief (3 copies)
<input type="checkbox"/> Declaration with <input type="checkbox"/> Power of Attorney	<input type="checkbox"/> Petition for Extension of Time
<input type="checkbox"/> Assignment & Recordation Cover Sheet	<input type="checkbox"/> Filing of Missing Parts
<input type="checkbox"/> Letter of Transmittal	<input type="checkbox"/> Express Mail Certificate
<input checked="" type="checkbox"/> Disclosure Statement 3 References	<input type="checkbox"/> Associate Power of Attorney
<input checked="" type="checkbox"/> Form PTO-FB-A820	<input type="checkbox"/> Petition for Expedited Issuance for _____
<input type="checkbox"/> Issue Fee Transmittal	<input type="checkbox"/> Foreign Filing License
<input type="checkbox"/> Fee Address Indication Form	<input type="checkbox"/> Provisional Cover Sheet
<input type="checkbox"/> Priority Document	<input type="checkbox"/> PTO-1390 (DO/EO/US) _____ pages
<input type="checkbox"/> Cert. of Correction under 37 CFR 1.322(a)	<input type="checkbox"/> Form PTO-1050



TECH CENTER 1600/2900

RECEIVED
APR 24 2003

WFM ✓

